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Editorial on the Research Topic
Protein Degradation Pathways in Parkinson’s Disease and Neurodegeneration
The most common neurodegenerative diseases of aging are characterized by intraneuronal
accumulations of aggregated proteins that are closely linked to pathogenesis and neuronal
loss. The formation of these inclusion bodies has been initially related to the biochemical
properties of their main protein components, which shared common fibrillization and aggregation
propensity (Ross and Poirier, 2004). Neuropathologically, the identification of the aggregated
protein helps the ultimate diagnosis. Thus, alpha-synuclein pathology is classically related to
Parkinson’s disease (PD), Tau and Amyloid-β to Alzheimer’s disease (AD), SOD1, TDP-43, and
C9orf72 to Amyotrophic Lateral Sclerosis/Frontotemporal Dementia (ALS/FTD), Huntingtin
to Huntington’s disease (HD). Interestingly, some of these pathologies overlap in the same
clinical entity (e.g., alpha-synuclein pathology in AD). Nevertheless, the etiological role of these
inclusions has been questioned and is still a matter of intense debate (Surmeier et al., 2017).
Efforts to uncover the mechanistic role of neuropathology have led to important advances in
cell biology and neurobiology pointing to the involvement of protein degradation pathways in
neurodegeneration, especially the ubiquitin-proteasome system (Tai and Schuman, 2008) and
autophagy (Scrivo et al., 2018).
In Parkinson’s disease, the study of the autophagy-lysosome pathway has rapidly progressed in
recent years. Autophagy is implicated in alpha-synuclein pathology as impairment in this process
causes alpha-synuclein accumulation (Obergasteiger et al., 2018). In addition, a number of genes
linked to familial PD have been found to play a role in the modulation of autophagy, especially
alpha-synuclein itself and leucine-rich repeat kinase 2 (LRRK2) (Manzoni and Lewis, 2013). Thus,
the importance of dissecting thesemolecular and cellular pathways, and understanding the intimate
regulation of PD-linked genes are crucially required to understand the pathogenic processes
underlying protein aggregation and neurodegeneration.
We have collected a Research Topic centered on protein aggregation, protein degradation and
quality control systems with a focus on how causal genes in PD and neurodegenerative diseases
are involved in these processes. These articles provide an overview on different aspects of these
processes and discuss how they can be involved in pathophysiology.
The review by Albanese et al. discusses the involvement of autophagy in brain aging and the
decline in its efficacy during senescence. The decrease in autophagy function is linked to the
accumulation of damaged organelles andmisfolded proteins, increasing the risk of cellular damage.
In neurons, the severity of this dysfunction is further aggravated by their post-mitotic nature
and the incapacity of diluting toxic species with subsequent cell divisions, possibly triggering
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neurodegeneration. Further, the authors explore how the PD-
linked gene LRRK2 is involved in autophagy regulation and how
mutations might affect its physiological function. Moreover, they
discuss the possible link to LRRK2-related neurodegeneration,
which is of importance, given the fact that LRRK2 is a major
pharmaceutical target for neuroprotection in PD.
Closely linked to its role in autophagy is the finding that
LRRK2 is a mediator of intracellular vesicle trafficking, which is
believed to play an important role in PD pathogenesis.
In this context, the review by Ebanks et al. analyses the
role of several genes linked to familial PD or associated at
genome-wide level in the modulation of vesicle dynamics
and the downstream functional consequences. The authors
identify key processes of intracellular vesicle trafficking
in which PD genes play crucial roles and that might be
involved in the early stages of the disease: vesicle fusion,
which is particularly relevant for neuronal transmission;
endocytosis, with functions spanning from synaptic vesicle
recycling to endosomal transport; the trans Golgi network,
through which the recently elucidated LRRK2-Rab signaling
system mediates vesicle recycling; lysosomal function,
critically related to protein degradation and proteostasis
with immediate consequences for neuropathology. The authors
posit that PD could be regarded as a “dysfunction of vesicular
trafficking,” with several etiologic agents converging on such
mechanisms and allowing to draw a unifying picture of
PD pathogenesis.
Consistent with this view, Rivero-Ríos et al. propose a
testable working model to study the effect of the LRRK2-
Rab axis in the modulation of the endolysosomal system.
They discuss the link between endolysosomal dysfunction and
alpha-synuclein aggregation, which could be regarded as a
common readout, but caused by distinct mechanisms. For
example, different cellular mechanisms (e.g., oligomerization,
lysosomal impairment, and lipid perturbations) might underlie
the same downstream effect, i.e., the accumulation of intracellular
aggregates of alpha-synuclein in patients with alpha-synuclein
mutations, GBA mutations or idiopathic PD. In the context
of LRRK2-PD, aberrant LRRK2-mediated phosphorylation of
Rab8a and Rab10 caused by PD-linked mutations in LRRK2
alters the endolysosomal functionality and could lead to neuronal
damage in the absence of alpha-synuclein pathology. When such
dysfunctions are paired with further lysosomal stress or damage
(e.g., mutations in lysosomal genes or environmental agents), the
formation of Lewy bodies would be triggered. Indeed, the authors
highlight that a proportion of LRRK2 PD cases do not present
with alpha-synuclein neuropathology.
The characterization of neuropathology in different forms
of parkinsonism is the subject of the Brief Research Report
from Mazzetti et al. Here, the authors histologically analyzed
human brain samples from patients who have suffered from
synucleinopathies (PD and Multiple System Atrophy) and a
tauopathy (Progressive Supranuclear Palsy). Specifically, they
investigated the localization of the histone deacetylase HDAC6
and its phosphorylated, active form. HDAC6 is unique in
its class as it targets cytoplasmic non-histone proteins and
mediates aggresome formation. The authors found that both
HDAC6 forms localize to pathological alpha-synuclein and Tau
inclusions. In addition, HDAC6 is in close vicinity of alpha-
synuclein in PD, as evidenced by a Proximity Ligation Assay. This
work sheds light on the biology of protein aggregates and opens
up the opportunity of further mechanistic studies to uncover
novel mechanisms of neuronal pathology.
Lastly, in their Mini Review Llanos-González et al.
discuss the possible central role of oxidative stress in the
pathogenesis of Alzheimer’s disease. In particular, the authors
hypothesize that oxidative stress underlies dysfunction in
several cellular domains critically involved in the early onset
of the disease. The “first responder” to oxidative-redox
imbalance are mitochondria, whose damage triggers a cascade
of neurotoxic events in the brain. In addition, oxidative stress
can severely impact proteostasis, protein quality control and
protein degradation. In this respect, the authors explore the
link with endoplasmic reticulum-associated degradation, the
unfolded protein response and autophagy. In conclusion, the
authors also discuss putative therapeutic approaches targeting
oxidative stress that could ameliorate the abovementioned
cellular processes.
The five articles collected in this Research Topic provide
an advanced update on the state-of-the-art of proteostasis
in neurodegeneration, with a prominent focus on PD. The
articles explore in further details intracellular vesicle trafficking
and its dysregulation in PD conditions, drawing mechanistic
links that are centered on proteins implicated in familial PD.
Detailed clarification of these processes could lead to the
elucidation of a unifying pathogenic process, which would
have a major impact on the design of novel, effective disease-
modifying therapies.
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